Sinopharm Group Co. Ltd. (FRA:X2S1)

Sinopharm Group Statistics

Total Valuation

Sinopharm Group has a market cap or net worth of EUR 7.05 billion. The enterprise value is 18.44 billion.

Market Cap	7.05B
Enterprise Value	18.44B

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	Jun 17, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.36%
Shares Change (QoQ)	-82.11%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	27.67%
Float	1.34B

Valuation Ratios

The trailing PE ratio is 8.31 and the forward PE ratio is 7.43.

PE Ratio	8.31
Forward PE	7.43
PS Ratio	0.10
PB Ratio	0.45
P/TBV Ratio	0.82
P/FCF Ratio	3.10
P/OCF Ratio	2.92
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.59, with an EV/FCF ratio of 8.12.

EV / Earnings	21.76
EV / Sales	0.27
EV / EBITDA	6.59
EV / EBIT	8.21
EV / FCF	8.12

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.63.

Current Ratio	1.35
Quick Ratio	1.07
Debt / Equity	0.63
Debt / EBITDA	3.79
Debt / FCF	4.39
Interest Coverage	6.31

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	12.24%
Revenue Per Employee	634,523
Profits Per Employee	7,830
Employee Count	108,217
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Sinopharm Group has paid 467.97 million in taxes.

Income Tax	467.97M
Effective Tax Rate	27.83%

Stock Price Statistics

The stock price has decreased by -8.20% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.20%
50-Day Moving Average	10.61
200-Day Moving Average	10.48
Relative Strength Index (RSI)	48.11
Average Volume (20 Days)	0

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sinopharm Group had revenue of EUR 68.67 billion and earned 847.35 million in profits. Earnings per share was 0.27.

Revenue	68.67B
Gross Profit	5.08B
Operating Income	2.08B
Pretax Income	1.68B
Net Income	847.35M
EBITDA	2.35B
EBIT	2.08B
Earnings Per Share (EPS)	0.27

Balance Sheet

The company has 4.64 billion in cash and 9.97 billion in debt, giving a net cash position of -5.33 billion.

Cash & Cash Equivalents	4.64B
Total Debt	9.97B
Net Cash	-5.33B
Net Cash Per Share	n/a
Equity (Book Value)	15.82B
Book Value Per Share	3.16
Working Capital	11.49B

Cash Flow

In the last 12 months, operating cash flow was 2.42 billion and capital expenditures -146.57 million, giving a free cash flow of 2.27 billion.

Operating Cash Flow	2.42B
Capital Expenditures	-146.57M
Free Cash Flow	2.27B
FCF Per Share	n/a

Margins

Gross margin is 7.40%, with operating and profit margins of 3.04% and 1.23%.

Gross Margin	7.40%
Operating Margin	3.04%
Pretax Margin	2.45%
Profit Margin	1.23%
EBITDA Margin	3.42%
EBIT Margin	3.04%
FCF Margin	3.31%

Dividends & Yields

This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 2.72%.

Dividend Per Share	0.30
Dividend Yield	2.72%
Dividend Growth (YoY)	-34.87%
Years of Dividend Growth	5
Payout Ratio	10.73%
Buyback Yield	0.36%
Shareholder Yield	3.08%
Earnings Yield	12.03%
FCF Yield	32.22%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sinopharm Group has an Altman Z-Score of 2.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.1
Piotroski F-Score	3